rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter

• Status: Completed
• Trial end date: 2005-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The trials in this protocol deals with the effect of pretreatment with rhTSH on radioiodine treatment of thyroid size and function, in patients with nontoxic and toxic nodular goiter. It is an introduction of a novel principle, based on prospective, randomized double blind investigations. Attached to this, we investigate the acute effects of rhTSH on thyroid size (measured by ultrasonography), both in healthy individuals and in patients with nontoxic nodular goiter. Thus, the investigations are divided into 4 categories listed below:

1. Prospective randomized double blind study of pretreatment with 0.3 mg recombinant human TSH for the effect of radioiodine in nontoxic multinodular goiter.

2. Prospective randomized double blind study of the pretreatment with 0.3 mg recombinant human TSH for the effect of radioiodine on thyroid size and function in patients with a very large (>100 ml) nontoxic or toxic goiter.

3. Does administration of 0.9 mg recombinant human TSH affect thyroid function and volume in healthy individuals? A randomized double-blind cross-over trial.

4. Does administration of 0.3 mg recombinant human TSH affect thyroid function and volume in healthy individuals and in patients with multinodular non-toxic goiter? A randomized double-blind cross-over trial.

As a final note we investigate, in a pilot-study;

5. The influence of rhTSH on thyroid radioiodine uptake in patients with hyperthyroidism treated with continuous block-replacement therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Odense University Hospital
• Treatments: Calcitonin

Criteria

Inclusion Criteria:

• Healthy volunteers with an intact thyroid gland

• Patients with nontoxic/subtoxic nodular goiter confirmed by ultrasonography

• Patients with toxic nodular goiter

• Patients with Graves' disease

Exclusion Criteria:

• Treatment with drugs that alter thyroid function or size (the last 3 months prior to inclusion)

• Prior 131I treatment

• Alcohol, medicine or drug abuse

• Pregnancy or lactation

• No safe contraception

• Participation in another clinical trial

• Allergic reaction towards rhTSH

• Fine needle biopsy without valid diagnostic criteria for benign disease

• Suspicion of malignancy, increased ionized serum calcium and/or serum calcitonin

• Incontinence

• Physically or psychic condition that hinders corporation

• Ischemic attack up till 3 months before inclusion